Fig. 2
From: Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines
MLN8237 inhibits the growth of human cancer cell lines. a Chemical structure and molecular weight of MLN8237 (Alisertib). b Effect of MLN8237 on p53-competent (H460 and H2429) and p53-deficient (H1299) human lung cancer cell lines. Cells were treated with the indicated concentrations of MLN8237 for 3 days, and the number of metabolically active viable cells per well was measured by MTS assay. Data are mean ± SD of triplicate wells. At 48 h after 100 nM MLN8237 treatment, cell survival of H460 dropped to 56%, HCC2429 to 50%, and H1299 to 77% compared to a DMSO-treated control. * p < 0.05, t-test, groups of 48 h and 72 h. c Dose dependent inhibition of AURKA activation by MLN8237. At 48 h after 100 nM MLN8237 treatment, phosphorylation of AURKA was decreased significantly in all cell lines